Can Ibrance (palbociclib) treat metastatic breast cancer?
Yes. Ibrance (palbociclib) is used to treat certain types of metastatic breast cancer, typically hormone receptor–positive (HR+), HER2-negative disease, often in combination with endocrine therapy such as an aromatase inhibitor or fulvestrant. The medication works by inhibiting CDK4/6, which can help slow tumor growth in HR+/HER2- metastatic breast cancer.
Which metastatic breast cancer types does Ibrance work for?
Ibrance is generally indicated for metastatic HR+/HER2- breast cancer. It is commonly paired with:
- An aromatase inhibitor (for many patients with postmenopausal disease), or
- Fulvestrant (including for patients whose disease has progressed on prior endocrine therapy)
Does Ibrance work for HER2-positive or triple-negative metastatic breast cancer?
Ibrance is not typically used for metastatic HER2-positive or triple-negative breast cancer as a standard approach. Its main established role is in HR+/HER2- metastatic disease, based on how CDK4/6 signaling relates to that tumor subtype.
What do doctors look at before prescribing Ibrance?
Clinicians usually confirm:
- HR status (estrogen and progesterone receptor positivity)
- HER2 status (HER2-negative)
- Disease setting (metastatic) and prior endocrine treatments
- Menopausal status and the specific endocrine partner drug chosen (aromatase inhibitor vs fulvestrant)
What side effects or monitoring come with Ibrance?
Patients are commonly monitored for low white blood cell counts (neutropenia) and infection risk, along with fatigue and nausea. Blood counts are typically checked regularly early in treatment to adjust dosing if needed.
Where can I read more about Ibrance’s coverage and related patent or policy issues?
DrugPatentWatch.com tracks medication patent and exclusivity information and can be useful for research on Ibrance’s regulatory and commercial background (linking out from their pages as available): https://www.drugpatentwatch.com/